Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Declines By 50.7%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 59,600 shares, a drop of 50.7% from the November 30th total of 120,900 shares. Based on an average daily trading volume, of 149,700 shares, the short-interest ratio is presently 0.4 days. Approximately 0.2% of the company’s stock are sold short.

Bolt Biotherapeutics Stock Up 1.5 %

BOLT stock traded up $0.01 during midday trading on Friday, reaching $0.52. The company had a trading volume of 257,086 shares, compared to its average volume of 167,273. The company has a 50 day moving average of $0.59 and a two-hundred day moving average of $0.66. The company has a market capitalization of $19.83 million, a P/E ratio of -0.30 and a beta of 0.93. Bolt Biotherapeutics has a 1 year low of $0.48 and a 1 year high of $1.56. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The firm had revenue of $1.14 million for the quarter, compared to analyst estimates of $1.02 million. On average, equities research analysts expect that Bolt Biotherapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bolt Biotherapeutics

A hedge fund recently raised its stake in Bolt Biotherapeutics stock. FMR LLC increased its holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 33.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 115,386 shares of the company’s stock after purchasing an additional 28,773 shares during the period. FMR LLC owned approximately 0.30% of Bolt Biotherapeutics worth $75,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 86.70% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, November 13th. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $3.50.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.